A61P 21 - Drugs for disorders of the muscular or neuromuscular system

Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
11/2001
11/15/2001	WO2001085779A2 Protein complexes and assays for screening anti-cancer agents
11/15/2001	WO2001085762A2 Cancer diagnosis and assays for screening anti-cancer agents
11/15/2001	WO2001085734A1 Benzoxazines for use in the treatment of parkinson's disease
11/15/2001	WO2001085727A1 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
11/15/2001	WO2001085695A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
11/15/2001	WO2001085677A1 Amino acid derivatives and their use as medicines
11/15/2001	WO2001085256A2 Critical illness neuropathy
11/15/2001	WO2001085194A1 Method and composition for the treatment of angiogenesis
11/15/2001	WO2001085178A1 Nutritional preparation comprising ribose and folic acid and medical use thereof
11/15/2001	WO2001085149A2 Felbamate derived compounds
11/15/2001	WO2001055172A3 ISOLATED COMPLEX COMPRISING A NNT-1 PROTEIN AND IN ADDITION AT LEAST A CLF-1 PROTEIN AND/OR A sCNTFRα PROTEIN
11/15/2001	WO2001040185B1 Compounds, compositions, and methods for stimulating neuronal growth and elongation
11/15/2001	WO2001012202A3 Use of chemical chelators as reversal agents for drug-induced neuromuscular block
11/15/2001	WO2000050872A9 A system for cell-based screening
11/15/2001	US20010041720 2-Amino-N-((1R)-2-((3R)-3-benzyl-3-(N,N',N' -trimethylhydrazinocarbonyl)piperidin-1-yl)-1-(1H-indol-3-ylmethyl)-2 -oxoethyl)-2-methylpropionamide; increasing rate and extent of growth, milk and wool production
11/15/2001	US20010041703 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair
11/15/2001	CA2409759A1 Method and composition for the treatment of angiogenesis
11/15/2001	CA2408486A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
11/15/2001	CA2408297A1 Cancer diagnosis and assays for screening anti-cancer agents
11/15/2001	CA2408213A1 Protein complexes and assays for screening anti-cancer agents
11/15/2001	CA2408002A1 Enzymatic assays for screening anti-cancer agents
11/15/2001	CA2407850A1 Cytoskeleton-associated proteins
11/15/2001	CA2407830A1 Amino acid derivatives and their use as medicines
11/15/2001	CA2407789A1 Benzoxazines for use in the treatment of parkinson's disease
11/15/2001	CA2407698A1 Repair of nerve damage
11/15/2001	CA2407697A1 Felbamate derived compounds
11/14/2001	EP1153121A2 Secreted proteins and polynucleotides encoding them
11/14/2001	EP1152761A2 Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
11/14/2001	EP1152759A2 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
11/14/2001	CN1321638A Method for preparing methylsulfonate trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperid-1-yl)-1-propanol
11/13/2001	US6316472 Heterosubstituted pyridine derivatives as PDE 4 inhibitors
11/13/2001	US6316021 Extensible mask including an adhesive matrix that can be stretched at least in the wet state
11/13/2001	US6314956 Treating lung defects associated hypoxemia or smooth muscle constriction; administer ethyl nitrite to human and monitor
11/08/2001	WO2001083775A2 Proteases
11/08/2001	WO2001083560A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001	WO2001083554A2 Anti-inflammatory compounds and uses thereof
11/08/2001	WO2001083547A2 Anti-inflammatory compounds and uses thereof
11/08/2001	WO2001083543A1 Human wingless-like gene
11/08/2001	WO2001083513A2 Antisense modulation of inhibitor of dna binding-1 expression
11/08/2001	WO2001083489A1 THIENO[2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
11/08/2001	WO2001083480A2 Dihydropyridine compounds and methods of use
11/08/2001	WO2001083434A2 P-(sulfonyl)-aryl and heteroaryls amines
11/08/2001	WO2001083425A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/08/2001	WO2001082975A2 Membrane-permeant peptide complexes for medical imaging
11/08/2001	WO2001082953A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001	WO2001082952A2 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
11/08/2001	WO2001041760A3 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/08/2001	WO2001037780A8 Urotensin-ii analogs
11/08/2001	WO2001029012A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001	WO2001029011A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001	US20010039350 Suitable for prophylaxis of diseases involving interleukin-1 beta such as septic shock, leukemia, hepatits, muscular degeneration, HIV infections, or degenerative joint diseases
11/08/2001	CA2414296A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2414290A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2407965A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001	CA2407959A1 Human wingless-like gene
11/08/2001	CA2407797A1 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001	CA2407785A1 Use of .alpha.-msh and epo for preventing or treating ischemic conditions
11/08/2001	CA2407746A1 Proteases
11/08/2001	CA2407399A1 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/08/2001	CA2407317A1 Dihydropyridine compounds and methods of use
11/08/2001	CA2405832A1 P-(sulfonyl)aryl and heteroaryls
11/08/2001	CA2405611A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/07/2001	EP1151995A1 Process for the preparation of the mesylate salt trihydrate of 1-(4-Hydroxyphenyl)-2-(4-Hydroxy-4-Phenylpiperidin-1-YL)-1-Propanol
11/07/2001	EP1151101A1 Prostacyclin-stimulating factor-2
11/07/2001	EP1150960A1 Polymorphic crystalline forms of celecoxib
11/07/2001	EP1150959A1 Solid-state form of celecoxib having enhanced bioavailability
11/07/2001	EP1150746A2 The use of 4-h-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
11/07/2001	EP1150673A1 Mono-acyloxy aralkyl neuromuscular relaxants
11/07/2001	EP1150658A2 Method for controlling liposome size
11/07/2001	EP0970043B1 Compounds consisting in particular of effectors of the central nervous system receptors sensitive to excitatory amino acids, preparation and biological applications
11/07/2001	EP0918469B1 Methods and compositions for increasing the anaerobic working capacity in tissues
11/07/2001	CN1320429A Medical liquor for treating injury
11/06/2001	US6313117 Succinate derivative compounds useful as cysteine protease inhibitors
11/06/2001	US6312708 Botulinum toxin implant
11/06/2001	US6312688 Tyrosine-phosphatase-related protein
11/06/2001	CA2250251C Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
11/03/2001	CA2345760A1 Pharmaceutical uses for fluoroalkoxybenzylamino and alkoxybenzylamino derivatives of nitrogen containing heterocycles
11/01/2001	WO2001081590A2 Protein phosphatases
11/01/2001	WO2001081585A2 A thymus expressed human cytochrome p450 (p450tec)
11/01/2001	WO2001081573A1 Edg8 receptor, its preparation and use
11/01/2001	WO2001081540A2 Growth factor which acts through erb b-4 rtk
11/01/2001	WO2001081415A2 Parathyroid hormone and parathyroid hormone-related protein antagonists
11/01/2001	WO2001081348A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO[3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
11/01/2001	WO2001081346A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta
11/01/2001	WO2001081343A2 Compounds for treating fibromyalgia and chronic fatigue syndrome
11/01/2001	WO2001081312A2 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
11/01/2001	WO2001081310A1 1-aroyl-piperidinyl benzamidines
11/01/2001	WO2001081309A2 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol
11/01/2001	WO2001081303A1 Pyrrolidine and piperidine derivatives and their use for the treament of neurodegenerative disorders
11/01/2001	WO2001041762A3 Valdecoxib compositions
11/01/2001	WO2001041761A3 Valdecoxib compositions
11/01/2001	WO2001038311A3 Pyrimidine derivatives as selective inhibitors of cox-2
11/01/2001	WO2001012233A3 Sustained release formulation of a peptide
11/01/2001	WO2000066111A9 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions
11/01/2001	US20010036927 Complexing
11/01/2001	CA2407493A1 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
11/01/2001	CA2407445A1 Use of 5-thio-, sulfinyl- and sulfonylpyrazolo¬3,4-b\|-pyridines as cyclin dependent kinase inhibitors
11/01/2001	CA2406725A1 Edg8 receptor, its preparation and use
11/01/2001	CA2406639A1 A thymus expressed human cytochrome p450 (p450tec)
11/01/2001	CA2406264A1 Protein phosphatases

1 ... 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 ... 233